Angiotensin II (Ang II) is an eight-amino-acid vasoactive peptide (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) that serves as the primary effector molecule of the renin-angiotensin-aldosterone system (RAAS). Synthesized predominantly by ACE1-mediated cleavage of angiotensin I in pulmonary and renal endothelium, Ang II functions as both a systemic hormone and local tissue autocrine/paracrine factor. It orchestrates blood pressure homeostasis, fluid balance, and—critically for cPNI—acts as a powerful pro-inflammatory signal through direct NF-κB activation.
Think of Ang II as the factory foreman who's been given too much authority during a crisis. Normally, when blood pressure drops (the factory's power supply weakens), the foreman (Ang II) steps in with emergency measures: he constricts the water pipes (vasoconstriction), orders the kidneys to retain every drop of water and salt (aldosterone release), and sends urgent memos to headquarters (sympathetic activation). He even turns on the emergency generators (oxidative stress via NADPH oxidase).
But here's the problem: if the foreman stays in crisis mode for too long—chronic stress, metabolic syndrome, sustained high salt intake—he starts damaging the very infrastructure he's supposed to protect. The constant pipe constriction causes cracks (endothelial dysfunction). The emergency generators produce toxic fumes (reactive oxygen species). The urgent memos become inflammatory manifestos (NF-κB activation), recruiting an aggressive security force (immune activation) that treats the factory's own workers as threats. What began as adaptive crisis management becomes a state of permanent emergency, with the foreman's orders causing atherosclerosis, insulin resistance, organ fibrosis, and chronic inflammation. The counterbalance would be ACE2 converting him to Ang 1-7—a much gentler supervisor who repairs instead of reacts.
Ang II formation and signaling follows a precise cascade:
Formation Pathway:
- Angiotensinogen (liver) → Angiotensin I (via renin from juxtaglomerular cells)
- Angiotensin I → Ang II (via ACE1 on pulmonary/renal endothelium)
- Alternative pathway: chymase and cathepsin G can also cleave angiotensin I to Ang II (ACE-independent)
Receptor Signaling:
Ang II binds two primary G-protein coupled receptors:
AT1 Receptor (primary pathological effects):
- Gq/11 coupling → phospholipase C activation → IP3/DAG second messengers
- IP3 → Ca²⁺ release → vasoconstriction (smooth muscle contraction)
- DAG → PKC activation → multiple downstream cascades
- NADPH oxidase activation → superoxide (O2⁻) production → oxidative stress
- Direct NF-κB translocation to nucleus (via IκB degradation)
- JAK2-STAT3 pathway activation → inflammatory gene transcription
- MAPK cascades (ERK1/2, JNK, p38) → cell growth, fibrosis, inflammation
- Sympathetic nervous system potentiation via AT1 receptors in brain/adrenal medulla
AT2 Receptor (generally opposing effects):
- Vasodilation via NO and bradykinin
- Anti-proliferative effects
- Typically expressed in fetal tissue; downregulated in adults
Key Downstream Effects:
graph TD
A[Ang II] --> B[AT1 Receptor]
B --> C[Vasoconstriction]
B --> D[Aldosterone Release]
B --> E[NADPH Oxidase Activation]
B --> F["NF-κB Activation"]
B --> G[Sympathetic Activation]
E --> H[Oxidative Stress]
H --> I[Endothelial Dysfunction]
F --> J[IL-6 Production]
F --> K["TNF-α Production"]
F --> L["IL-1β Production"]
D --> M["Na+/H2O Retention"]
M --> N["Blood Pressure ↑"]
C --> N
J --> O[Insulin Resistance]
K --> O
L --> O
H --> O
F --> P[Adhesion Molecules VCAM-1, ICAM-1]
P --> Q[Atherosclerosis]
I --> Q
Metabolic Effects:
- Insulin receptor substrate-1 (IRS-1) serine phosphorylation → insulin resistance
- GLUT4 transporter downregulation → decreased glucose uptake
- Hepatic gluconeogenesis stimulation
- Adipocyte lipolysis inhibition → visceral fat accumulation
Degradation Pathway:
- ACE2 converts Ang II → Ang 1-7 (protective, anti-inflammatory peptide)
- Aminopeptidases degrade Ang II → smaller inactive fragments
- Plasma half-life: 15-30 seconds (tissue half-life 1-2 minutes)
Ang II represents a critical convergence point between cardiovascular, metabolic, and immune dysregulation—making it central to cPNI practice. Chronic elevation is not merely a blood pressure issue but a driver of systemic metaflammation.
Relevant Patient Populations:
- Metabolic syndrome/Type 2 Diabetes: Ang II-induced insulin resistance creates a vicious cycle where hyperinsulinemia further activates RAAS, perpetuating inflammation and metabolic dysfunction
- Cardiovascular disease: AT1 receptor activation drives atherosclerotic plaque formation through oxidative stress, endothelial dysfunction, and inflammatory cell recruitment
- Chronic kidney disease: Ang II causes glomerular hyperfiltration, podocyte injury, and progressive fibrosis
- Neuroinflammation/cognitive decline: Crosses blood-brain barrier at circumventricular organs; activates microglia and contributes to Alzheimer's pathology
- Chronic pain syndromes: Pro-inflammatory signaling sensitizes peripheral and central pain pathways
Metamodel Connections:
This exemplifies selfish system dysregulation—the RAAS prioritizes immediate cardiovascular survival (maintain blood pressure) at the expense of long-term metabolic and immune health. The system becomes increasingly "selfish" under chronic stress, creating:
- Metabolic system sacrifice: Insulin resistance ensures glucose availability for brain/heart but destroys metabolic flexibility
- Immune system hijacking: NF-κB activation treats metabolic stress as infection, producing chronic low-grade inflammation
- Allostatic overload: Prolonged Ang II elevation exemplifies allostatic load accumulation, where adaptive responses become maladaptive
Evolutionary Mismatch:
RAAS evolved for acute challenges (hemorrhage, dehydration, physical threat). Modern chronic activation occurs from:
- Sedentarism (reduced skeletal muscle contraction decreases venous return)
- High sodium/low potassium diets (reverse of ancestral ~10:1 K:Na ratio)
- Chronic psychological stress (HPA-RAAS cross-activation)
- Sleep deprivation (disrupted circadian aldosterone/renin rhythms)
Clinical Thresholds:
- Normal plasma Ang II: 10-30 pg/mL (fasting)
- Hypertensive patients: often 30-60 pg/mL
- Elevated aldosterone-to-renin ratio (>30) suggests primary hyperaldosteronism but also chronic Ang II stimulation
Intervention Implications:
- Pharmaceutical: ACE inhibitors block Ang II formation; ARBs (angiotensin receptor blockers) block AT1 receptors—both reduce inflammation beyond blood pressure effects
- Lifestyle: Potassium-rich diet, regular movement (skeletal muscle contraction enhances venous return, reducing compensatory RAAS activation), stress management (reduces HPA-RAAS cross-talk)
- Nutraceutical: Aged garlic extract (ACE inhibitory activity), resveratrol (AT1 receptor downregulation), omega-3 fatty acids (compete for membrane AT1 receptor positioning)
- Testing consideration: Plasma renin activity and aldosterone together reveal RAAS tone; elevated aldosterone with suppressed renin suggests chronic Ang II-independent activation
Exam Key: Understanding that Ang II activates NF-κB directly means chronic RAAS activation IS chronic inflammation—this is why ACE inhibitors reduce cardiovascular events beyond their blood pressure effects. The protective ACE2/Ang 1-7 axis represents the resolution arm of RAAS.
- Eight amino acid sequence: Asp-Arg-Val-Tyr-Ile-His-Pro-Phe
- Plasma half-life: 15-30 seconds; tissue half-life: 1-2 minutes (extremely rapid turnover)
- AT1 receptors mediate pathological effects; AT2 receptors provide limited opposing effects
- Directly activates NF-κB transcription factor independently of cytokine signaling
- NADPH oxidase activation produces superoxide at 2-3× baseline with sustained Ang II exposure
- Normal plasma concentration: 10-30 pg/mL (can reach 60+ pg/mL in hypertension)
- Crosses blood-brain barrier at circumventricular organs (organum vasculosum laminae terminalis, subfornical organ, area postrema)
- Stimulates aldosterone release from zona glomerulosa (adrenal cortex) within 10-15 minutes
- Reduces insulin sensitivity by 30-40% through IRS-1 serine phosphorylation
- Can be converted to protective Ang 1-7 by ACE2 (degradation pathway ratio determines net inflammatory tone)
- Chronic elevation causes cardiac hypertrophy via TGF-β and collagen deposition
- Increases sympathetic outflow from rostral ventrolateral medulla (RVLM) in brainstem
- Stimulates thirst (dipsogenic effect) via subfornical organ and organum vasculosum
- ACE inhibitors reduce cardiovascular mortality by 20-25%, partly through anti-inflammatory mechanisms
- Tissue RAAS (local autocrine/paracrine) often more pathogenic than circulating Ang II
- ACE — cleaves angiotensin I to form Ang II; primary formation enzyme
- angiotensin I — immediate precursor; decapeptide substrate for ACE
- ACE2 — degrades Ang II to protective Ang 1-7; counterbalancing enzyme
- Ang 1-7 — protective peptide formed from Ang II; opposes AT1 signaling via MAS receptor
- MAS receptor — receptor for Ang 1-7; mediates vasodilation, anti-inflammatory effects
- renin — initiates RAAS cascade by cleaving angiotensinogen
- aldosterone — mineralocorticoid released by Ang II; drives sodium/water retention
- NF-κB — transcription factor directly activated; central inflammatory mediator
- chronic low-grade inflammation — sustained NF-κB activation creates metaflammation
- IL-6 — upregulated via NF-κB; contributes to insulin resistance and cachexia
- TNF-α — produced via AT1/NF-κB pathway; amplifies insulin resistance
- IL-1β — inflammasome-dependent cytokine increased by oxidative stress from Ang II
- insulin resistance — directly induced through IRS-1 phosphorylation and GLUT4 suppression
- oxidative stress — NADPH oxidase produces superoxide; damages endothelium
- Reactive Oxygen Species — O2⁻, H2O2 generated by NADPH oxidase activation
- sympathetic nervous system — potentiated at multiple levels (adrenal, RVLM, peripheral)
- HPA axis — cross-activated with RAAS under chronic stress (CRH stimulates renin release)
- vasopressin — release stimulated for water retention; works synergistically with aldosterone
- endothelial dysfunction — caused by oxidative stress, reduced NO bioavailability
- atherosclerosis — Ang II promotes via inflammation, oxidative stress, VCAM-1 expression
- VCAM-1 — vascular adhesion molecule upregulated by NF-κB; recruits monocytes
- TGF-beta — profibrotic cytokine stimulated by AT1 receptor; causes organ fibrosis
- ACE inhibitors — block Ang II formation; reduce cardiovascular events and inflammation
- Chronic Kidney Disease — progression driven by Ang II-mediated glomerular damage
- Type 2 Diabetes — Ang II causes and is exacerbated by insulin resistance
- metaflammation — Ang II exemplifies metabolic-immune axis dysregulation
- allostatic load — chronic Ang II elevation represents accumulated adaptive cost